1. Executive Summary
• 1.1 Key Findings
• 1.2 Market Snapshot: Value, Treated Patients and Revenue per Patient, 2024, 2025 and 2030
• 1.3 Analyst Viewpoint
2. Research Methodology
• 2.1 Research Scope and Market Definition
• 2.2 Data Sources: Primary and Secondary Research
• 2.3 Market Sizing Approach: Patient-Based and Sales-Based Models
• 2.4 Patient Funnel Construction and Assumptions
• 2.5 Pricing and Revenue per Patient Estimation
• 2.6 Pipeline Tracking and Probability-of-Success Adjustments
• 2.7 Forecasting Assumptions and Data Triangulation
• 2.8 Abbreviations
3. Global Neuropathic Pain Treatment Market Outlook
• 3.1 Market Value, 2020–2030 (US$ Billion)
• 3.2 Year-on-Year Growth Momentum, 2021–2030
• 3.3 Treated Patient Population, 2020–2030
• 3.4 Revenue per Treated Patient, 2020–2030
4. Epidemiology and Patient Funnel
• 4.1 Prevalence of Neuropathic Pain by Region
• 4.2 Diagnosis Rates
• 4.3 Treatment Rates and Guideline Adherence
• 4.4 Treatment Response and Unmet Need
5. Market Dynamics
• 5.1 Drivers
• 5.1.1 Non-Opioid Therapeutic Innovation
• 5.1.2 Rising Diabetes and Cancer Survivorship
• 5.1.3 Ageing Populations and Shingles Burden
• 5.2 Restraints
• 5.2.1 Generic Erosion of Established Therapies
• 5.2.2 Step Therapy and Reimbursement Barriers
• 5.3 Opportunities
• 5.3.1 Underserved Indications (CIPN, Central Pain, Trigeminal Neuralgia)
• 5.3.2 Topical and Localized Therapies
• 5.3.3 Emerging-Market Diagnosis Expansion
• 5.4 Challenges
• 5.4.1 High Placebo Response and Clinical Attrition
• 5.4.2 Opioid Prescribing Restrictions
6. Global Market Analysis by Drug Class
• 6.1 Gabapentinoids
• 6.2 SNRIs and TCAs
• 6.3 Topical Agents
• 6.4 Opioids and Tramadol
• 6.5 Sodium-Channel Anticonvulsants
• 6.6 Novel Non-Opioid Agents
• 6.7 Others
7. Global Market Analysis by Indication
• 7.1 Painful Diabetic Peripheral Neuropathy
• 7.2 Painful Radiculopathy and Sciatica
• 7.3 Postherpetic Neuralgia
• 7.4 Chemotherapy-Induced Peripheral Neuropathy
• 7.5 Post-Surgical and Post-Traumatic Neuropathic Pain
• 7.6 Central Neuropathic Pain
• 7.7 Trigeminal Neuralgia
• 7.8 Others
8. Global Market Analysis by Route of Administration
• 8.1 Oral
• 8.2 Topical
• 8.3 Injectable
9. Global Market Analysis by Distribution Channel
• 9.1 Hospital Pharmacies
• 9.2 Retail Pharmacies
• 9.3 Online Pharmacies
10. Generic vs Branded Market Analysis
• 10.1 Prescription Share
• 10.2 Value Share
• 10.3 Loss-of-Exclusivity Timeline
11. Regional Analysis (Value, Treated Patients, Revenue per Patient, 2020–2030)
• 11.1 North America (U.S., Canada, Mexico)
• 11.2 Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• 11.3 Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, Rest of Asia Pacific)
• 11.4 Latin America (Brazil, Argentina, Rest of Latin America)
• 11.5 Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa)
12. Clinical Pipeline Analysis
• 12.1 Pipeline by Phase
• 12.2 Pipeline by Mechanism of Action
• 12.3 Key Late-Stage Programmes and Expected Readouts
• 12.4 Launch Timeline and Peak Sales Scenarios
13. Regulatory and Reimbursement Landscape
• 13.1 United States (FDA, Payer Policies)
• 13.2 European Union (EMA, HTA)
• 13.3 Japan and China
• 13.4 Opioid Prescribing Regulations
14. Competitive Landscape
• 14.1 Market Structure and Concentration
• 14.2 Recent Mergers, Licensing and Restructuring
• 14.3 Epignosis Insights Competitive Assessment Framework (EICAF)
• 14.4 EICAF Scoring Method and Company Rankings
15. Company Profiles
• 15.1 Viatris
• 15.2 Eli Lilly and Company
• 15.3 Grünenthal (incl. Averitas Pharma)
• 15.4 Daiichi Sankyo
• 15.5 Vertex Pharmaceuticals
• 15.6 Lexicon Pharmaceuticals
• 15.7 Keenova Therapeutics (formerly Mallinckrodt and Endo)
• 15.8 Teva Pharmaceuticals
• 15.9 Sun Pharmaceutical Industries
• 15.10 Zydus Lifesciences
• 15.11 Lupin
• 15.12 Dr. Reddy's Laboratories
• 15.13 Cipla
• 15.14 Aurobindo Pharma
• Each profile: Company Overview, Neuropathic Pain Portfolio, Pipeline, Financial Snapshot, Recent Developments
16. Strategic Recommendations
• 16.1 For Innovator Companies
• 16.2 For Generic Manufacturers
• 16.3 For Payers and Healthcare Systems
• 16.4 For Investors
17. Appendix
• 17.1 List of Tables
• 17.2 List of Figures
• 17.3 Disclaimer